Does Rallies show Form 4 insider transactions for CGEM?

Yes. Rallies tracks CGEM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CGEM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CGEM. It does not provide personalized investment advice.

CGEM (Cullinan Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Cullinan Therapeutics, Inc. Common Stock (CGEM) is a publicly traded Healthcare sector company. As of May 21, 2026, CGEM trades at $14.03 with a market cap of $913.88M and a P/E ratio of 0.00. CGEM moved +0.95% today. Year to date, CGEM is +43.44%; over the trailing twelve months it is +81.39%. Its 52-week range spans $5.68 to $17.98. Analyst consensus is strong buy with an average price target of $30.00. Rallies surfaces CGEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CGEM stock inside the company?

Recent CGEM insider activity includes Michaelson Jennifer sold 7.80K, Michaelson Jennifer sold 200, Michaelson Jennifer sold 8.00K, Michaelson Jennifer sold 1.78K, and Michaelson Jennifer sold 3.60K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CGEM Key Metrics

Key financial metrics for CGEM
Metric	Value
Price	$14.03
Market Cap	$913.88M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$17.98
52-Week Low	$5.68
Volume	65
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-219.88M
Gross Margin	0.00%

Recent CGEM Insider Trades

Michaelson Jennifer sold 7.80K (~$113.88K) on May 5, 2026.
Michaelson Jennifer sold 200 (~$3.12K) on May 5, 2026.
Michaelson Jennifer sold 8.00K (~$125.44K) on Mar 5, 2026.
Michaelson Jennifer sold 1.78K (~$25.17K) on Feb 25, 2026.
Michaelson Jennifer sold 3.60K (~$52.11K) on Feb 24, 2026.

Latest CGEM News

Cullinan’s $393M Cash Runway, Zipalertinib NDA Accepted, CLN-978 Data in June — May 7, 2026
Cullinan Therapeutics Holds $439M, Schedules Q2 CLN-978 Data and Zipalertinib NDA — Mar 10, 2026
Cullinan Therapeutics Prepares Q2 2026 CLN-978 Data Readout with AML Fast Track — Feb 13, 2026

CGEM Analyst Consensus

11 analysts cover CGEM: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.00.

Common questions about CGEM

Who is trading CGEM stock inside the company?: Recent CGEM insider activity includes Michaelson Jennifer sold 7.80K, Michaelson Jennifer sold 200, Michaelson Jennifer sold 8.00K, Michaelson Jennifer sold 1.78K, and Michaelson Jennifer sold 3.60K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CGEM?: Yes. Rallies tracks CGEM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CGEM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CGEM. It does not provide personalized investment advice.